Oren Cohen, MD, promoted to Quintiles' senior vice president of clinical research strategies
Research Triangle Park, NC-April 16, 2008-Quintiles Transnational (www.quintiles.com) today announced the appointment of Oren Cohen, MD, as senior vice president, clinical research strategies.
Most recently, Cohen held the position of chief medical and scientific officer. In his new role, Cohen will be responsible for evaluating and implementing new clinical research strategies, part of the company's "shape the future" objective. He also will continue to serve as managing director of Quintiles public health and government services.
Cohen is also a consulting professor of medicine at Duke University School of Medicine. He earned a medical degree from Duke University and completed his residency at New York Hospital/Cornell University Medical Center and his fellowship in infectious diseases at the National Institutes of Health. He is board-certified in internal medicine and infectious diseases and has written more than 50 scientific articles and book chapters. He is a fellow of the Infectious Diseases Society of America and serves as a reviewer for several highly respected medical journals. He has won numerous awards for his professional achievements and has presented his work at dozens of conferences around the world.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.